Live News EQUITY M impact Jun 23, 2026, 08:05 PM UTC

AGMB Designs NOV-ERA Study

Agomab announces design of NOV-ERA Phase 2b study with Ontunisertib in Fibrostenosing Crohn's Disease

SQUAWKNEWS Updated Jun 23, 2026, 08:05 PM UTC

AGMB - Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease